Contributed Commentary by Ritish Patnaik, Curve Biosciences
April 3, 2026 | For decades, blood testing innovation has focused on improving patient testing for earlier and faster intervention. Advances in sequencing, automation, and molecular testing have dramatically improved our ability to biologically monitor patients. But as powerful as these technologies have become, they often still operate within a limited framework: they look for a biomarker panel that constitutes a single signal tied to a single disease.
Biology rarely works that way.
Chronic diseases do not exist in isolation. They unfold across organs and biological systems, often developing silently over years before symptoms appear. As our understanding of disease biology evolves, blood testing must evolve with it. The next generation of blood tests will need to move beyond single-organ biology and toward a more integrated understanding of how the entire body responds to disease. In short, the future of blood testing will depend on interpreting signals across the whole body.
This shift is becoming increasingly important as chronic disease rates continue to rise globally. Aging populations, changing lifestyles, and longer life expectancy have created a growing cohort of patients living with long-term conditions that require ongoing monitoring rather than one-time diagnosis. In the U.S. alone, tens of millions of adults are managing chronic diseases that require continuous evaluation and treatment adjustment.
Yet many of the tools that clinicians rely on today were not designed for this kind of longitudinal care.
Take liver disease as an example. Patients with cirrhosis face a significantly increased risk of developing liver cancer, and clinical guidelines recommend regular monitoring using imaging techniques such as ultrasound combined with an outdated blood test that has not been innovated on for decades; alpha-feto protein. These tools are rarely effective with limitations in sensitivity and accessibility, particularly for detecting disease progression at earlier stages. New treatments like focused ultrasound can liquify liver tumors, but only if they are found early.
More broadly, monitoring chronic disease often requires invasive procedures, expensive imaging, or indirect biomarkers that only provide partial insight into what is happening inside the body. As therapies become more sophisticated, including new metabolic treatments, biologics, and emerging classes of drugs, the need for better monitoring tools is becoming more urgent.
Blood tests must evolve from simple detection toward continuous biological monitoring.
One promising direction is the use of circulating cell-free DNA as a window into organ health. Fragments of DNA released into the bloodstream originate from cells throughout the body. In healthy individuals, most circulating DNA comes from blood cells themselves, with a smaller portion originating from organs. In people with chronic disease, however, damaged tissues release far greater quantities of DNA into circulation, creating a richer but more complex biological signal.
Interpreting these signals is challenging. In patients with chronic disease, a significant portion of circulating DNA in plasma originates from non-diseased organs that have been distressed by the chronic condition, meaning that signals from the diseased organs can easily be obscured by biological noise from the distressed, non-diseased organs. However, tissue-first advances in computational biology, machine learning, and large-scale biological datasets are beginning to make it possible to separate meaningful chronic disease signals from background organ noise.
This is where a new paradigm is emerging: combining large biological reference datasets with computational models capable of interpreting signals from across the body.
Some emerging approaches are built on large molecular atlases that map how DNA patterns differ across tissues and disease states. By training algorithms on hundreds of thousands of tissue samples spanning multiple organs and disease types, researchers can begin to identify patterns that reveal how diseases affect the body as a whole.
This approach, sometimes described as “Whole-Body Intelligence,” aims to transform blood tests into tools that can monitor the biological state of organs throughout the body.
Rather than searching for a biomarker panel for a single organ, these systems analyze patterns across many biological signals simultaneously. The result is a more comprehensive picture of how disease affects different organs over time. This approach has the potential to transform how chronic diseases are monitored.
For clinicians, whole-body insights could provide earlier warnings that a diseased organ is progressing, that a therapy is not working as expected, or that other organs are progressing to disease due to systemic distress. For patients, it could mean fewer invasive procedures and more accessible monitoring through routine blood tests. And for healthcare systems, better monitoring tools could improve treatment decisions and reduce unnecessary interventions. The implications extend beyond patient care.
Pharmaceutical companies increasingly need better biomarkers to evaluate how therapies affect organ systems, particularly as drugs expand into complex chronic conditions such as metabolic diseases and inflammatory disorders. Payers and regulators are also seeking stronger biological evidence that treatments deliver measurable improvements in patient outcomes. Blood testing capable of monitoring biological changes across organs could help provide that evidence.
Importantly, this shift toward Whole-Body Intelligence reflects a broader transformation in medicine. Healthcare is moving from reactive treatment toward proactive management of disease. Precision medicine initiatives, advances in computational biology, and the growing availability of real-world clinical data are all converging to create a more systems-level understanding of human health.
Blood tests will play a central role in this transformation. The next generation of blood tests will not simply confirm whether a disease is present. They will track how diseases evolve, how organs respond to therapy, and how biological systems interact over time. By capturing these dynamics, blood tests can help physicians intervene earlier, tailor treatments more precisely, and ultimately improve outcomes for patients living with chronic disease.
The challenge ahead is ensuring that these new approaches are rigorously validated, clinically integrated, and accessible to the patients who need them most. As medicine becomes more complex and more personalized, the blood tests guiding clinical decisions must become equally sophisticated. The future of blood testing will not be defined by a single organ signal or a faster assay. It will be defined by our ability to understand the biology of the entire human body.
Ritish Patnaik, Ph.D., is the CEO and co-founder of Curve Biosciences, which uses Whole-Body Intelligence to monitor chronic diseases with blood tests. His work focuses on combining biological datasets and machine learning to better understand how diseases affect organs and systems across the human body. He can be reached at ritish@curvebio.com.